drugset / Trial / NCT05191784
GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of GX-I7 in combination with bevacizumab in subjects with recurrent glioblastoma.
Timeline
- Start
- 2022-01-26
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | NT-I7 | Protein / enzyme biologic | — | Intramuscular |